Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer

Trédaniel, J.; Barlési, F.; Le Péchoux, C.; Lerouge, D.; Pichon, É.; Le Moulec, S.; Moreau, L.; Friard, S.; Westeel, V.; Petit, L.; Carré, O.; Guichard, F.; Raffy, O.; Villa, J.; Prévost, A.; Langlais, A.; Morin, F.; Wislez, M.; Giraud, P.; Zalcman, G.; Mornex, F.

Published in

Elsevier, Cancer Radiothérapie, 5(26), p. 670-677, 2022

DOI: 10.1016/j.canrad.2021.12.005

Tools

Export citation

Search in Google Scholar

Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer

Journal article published in 2022 by J. Trédaniel, F. Barlési, C. Le Péchoux, D. Lerouge, É. Pichon, S. Le Moulec, L. Moreau, S. Friard, V. Westeel, L. Petit, O. Carré, F. Guichard, O. Raffy, J. Villa, A. Prévost and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer